Business Description
NeuroPace Inc
NAICS : 423450
SIC : 5047
ISIN : US6412881053
Description
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.91 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 3.01 | |||||
| Debt-to-EBITDA | -5.11 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -3.27 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.3 | |||||
| 3-Year EBITDA Growth Rate | 30.7 | |||||
| 3-Year EPS without NRI Growth Rate | 24.6 | |||||
| 3-Year FCF Growth Rate | 25.3 | |||||
| 3-Year Book Growth Rate | -55.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 32.94 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.95 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.97 | |||||
| 9-Day RSI | 30.37 | |||||
| 14-Day RSI | 35.54 | |||||
| 3-1 Month Momentum % | 43.74 | |||||
| 6-1 Month Momentum % | 58.71 | |||||
| 12-1 Month Momentum % | 164.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.63 | |||||
| Quick Ratio | 5.7 | |||||
| Cash Ratio | 4.51 | |||||
| Days Inventory | 212.66 | |||||
| Days Sales Outstanding | 54.31 | |||||
| Days Payable | 50.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 | |||||
| Shareholder Yield % | -6.57 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74.83 | |||||
| Operating Margin % | -22.86 | |||||
| Net Margin % | -29.42 | |||||
| EBITDA Margin % | -16.97 | |||||
| FCF Margin % | -21.52 | |||||
| ROE % | -186.98 | |||||
| ROA % | -25.09 | |||||
| ROIC % | -65.82 | |||||
| 3-Year ROIIC % | 10.34 | |||||
| ROC (Joel Greenblatt) % | -57.25 | |||||
| ROCE % | -19 | |||||
| Moat score | 4 | |||||
| Tariff score | 6 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.74 | |||||
| PB Ratio | 14.28 | |||||
| Price-to-Tangible-Book | 14.28 | |||||
| EV-to-EBIT | -22.33 | |||||
| EV-to-Forward-EBIT | -16.21 | |||||
| EV-to-EBITDA | -25.15 | |||||
| EV-to-Forward-EBITDA | -16.38 | |||||
| EV-to-Revenue | 4.27 | |||||
| EV-to-Forward-Revenue | 3.75 | |||||
| EV-to-FCF | -19.83 | |||||
| Price-to-GF-Value | 1.31 | |||||
| Price-to-Net-Current-Asset-Value | 30.2 | |||||
| Earnings Yield (Greenblatt) % | -4.48 | |||||
| FCF Yield % | -5.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NPCE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeuroPace Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 84.306 | ||
| EPS (TTM) ($) | -0.84 | ||
| Beta | 2.12 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.89 | ||
| Volatility % | 71.26 | ||
| 14-Day RSI | 35.54 | ||
| 14-Day ATR ($) | 0.967599 | ||
| 20-Day SMA ($) | 12.092 | ||
| 12-1 Month Momentum % | 164.28 | ||
| 52-Week Range ($) | 5.45 - 18.975 | ||
| Shares Outstanding (Mil) | 32.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeuroPace Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeuroPace Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeuroPace Inc Frequently Asked Questions
What is NeuroPace Inc(NPCE)'s stock price today?
The current price of NPCE is $10.57. The 52 week high of NPCE is $18.98 and 52 week low is $5.45.
When is next earnings date of NeuroPace Inc(NPCE)?
The next earnings date of NeuroPace Inc(NPCE) is 2025-08-13 Est..
Does NeuroPace Inc(NPCE) pay dividends? If so, how much?
NeuroPace Inc(NPCE) does not pay dividend.
Guru Commentaries on NAS:NPCE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers